DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,616 filers reported holding DANAHER CORPORATION in Q3 2020. The put-call ratio across all filers is 1.03 and the average weighting 0.7%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $418,173,575 | +4.8% | 1,685,504 | +1.4% | 1.60% | +9.8% |
| Q2 2023 | $398,909,332 | -3.6% | 1,662,122 | +1.2% | 1.46% | -11.7% |
| Q1 2023 | $413,940,702 | -4.7% | 1,642,361 | +0.4% | 1.65% | -12.4% |
| Q4 2022 | $434,272,110 | +4.8% | 1,636,170 | +2.0% | 1.89% | -0.8% |
| Q3 2022 | $414,252,000 | +7.4% | 1,603,826 | +5.4% | 1.90% | +11.2% |
| Q2 2022 | $385,750,000 | -15.2% | 1,521,577 | -1.8% | 1.71% | +7.3% |
| Q1 2022 | $454,722,000 | -11.6% | 1,550,207 | -0.9% | 1.59% | -1.2% |
| Q4 2021 | $514,540,000 | +7.5% | 1,563,904 | -0.5% | 1.61% | -1.0% |
| Q3 2021 | $478,710,000 | +10.7% | 1,572,428 | -2.4% | 1.63% | +8.8% |
| Q2 2021 | $432,249,000 | +20.1% | 1,610,704 | +0.7% | 1.50% | +10.3% |
| Q1 2021 | $359,974,000 | +1.1% | 1,599,314 | -0.3% | 1.36% | +4.0% |
| Q4 2020 | $356,217,000 | +3.0% | 1,603,569 | -0.2% | 1.31% | -11.0% |
| Q3 2020 | $346,008,000 | +18.1% | 1,606,872 | -3.0% | 1.47% | +5.1% |
| Q2 2020 | $293,039,000 | +28.0% | 1,657,182 | +0.2% | 1.40% | -2.4% |
| Q1 2020 | $228,948,000 | -16.8% | 1,654,129 | -7.7% | 1.43% | +1.2% |
| Q4 2019 | $275,176,000 | +6.6% | 1,792,914 | +0.3% | 1.41% | -4.9% |
| Q3 2019 | $258,105,000 | -0.2% | 1,787,058 | -1.2% | 1.49% | +0.5% |
| Q2 2019 | $258,604,000 | +12.1% | 1,809,430 | +3.5% | 1.48% | +5.1% |
| Q1 2019 | $230,764,000 | +35.1% | 1,747,950 | +5.5% | 1.41% | +13.0% |
| Q4 2018 | $170,782,000 | -3.9% | 1,656,146 | +1.2% | 1.24% | +14.3% |
| Q3 2018 | $177,794,000 | +10.8% | 1,636,238 | +0.6% | 1.09% | -0.2% |
| Q2 2018 | $160,450,000 | +1.9% | 1,625,962 | +1.1% | 1.09% | -2.1% |
| Q1 2018 | $157,517,000 | -1.3% | 1,608,796 | -6.4% | 1.11% | +2.9% |
| Q4 2017 | $159,593,000 | +7.8% | 1,719,385 | -0.4% | 1.08% | -2.4% |
| Q3 2017 | $148,028,000 | +2.4% | 1,725,666 | +0.7% | 1.11% | +2.2% |
| Q2 2017 | $144,605,000 | +3.3% | 1,713,532 | +4.7% | 1.09% | -3.7% |
| Q1 2017 | $139,971,000 | +13.7% | 1,636,431 | +3.5% | 1.13% | +2.5% |
| Q4 2016 | $123,119,000 | +8.5% | 1,581,691 | +9.3% | 1.10% | +9.8% |
| Q3 2016 | $113,446,000 | -17.8% | 1,447,202 | +6.0% | 1.00% | -22.0% |
| Q2 2016 | $137,951,000 | +20.9% | 1,365,853 | +13.5% | 1.29% | +19.6% |
| Q1 2016 | $114,149,000 | +9.9% | 1,203,350 | +7.6% | 1.08% | +10.3% |
| Q4 2015 | $103,831,000 | -0.9% | 1,117,916 | -9.1% | 0.98% | +7.5% |
| Q3 2015 | $104,805,000 | +17.1% | 1,229,960 | +17.6% | 0.91% | +576.9% |
| Q2 2015 | $89,506,000 | -3.4% | 1,045,755 | -4.2% | 0.13% | -6.3% |
| Q1 2015 | $92,670,000 | -3.8% | 1,091,519 | -2.8% | 0.14% | -8.3% |
| Q4 2014 | $96,281,000 | +3.9% | 1,123,348 | -7.9% | 0.16% | -1.9% |
| Q3 2014 | $92,697,000 | -6.2% | 1,220,023 | -2.8% | 0.16% | -1.2% |
| Q2 2014 | $98,833,000 | +2.1% | 1,255,345 | -2.8% | 0.16% | +0.6% |
| Q1 2014 | $96,824,000 | -5.1% | 1,290,991 | -2.3% | 0.16% | -5.3% |
| Q4 2013 | $101,999,000 | +6.2% | 1,321,238 | -4.6% | 0.17% | -1.2% |
| Q3 2013 | $96,011,000 | +5.1% | 1,385,058 | -4.1% | 0.17% | -5.5% |
| Q2 2013 | $91,394,000 | – | 1,443,818 | – | 0.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |